Lampalizumab
Lampalizumab (pronunciation: lam-pa-li-zu-mab) is a monoclonal antibody designed for the treatment of geographic atrophy, a form of age-related macular degeneration (AMD).
Etymology
The name "Lampalizumab" is derived from the International Nonproprietary Names (INN), where "zu" indicates humanized, "mab" stands for monoclonal antibody, and "Lampa" is a unique stem.
Pharmacology
Lampalizumab works by inhibiting the activity of complement factor D, a protein involved in the complement system, which is part of the immune system. By inhibiting this protein, Lampalizumab can potentially slow down the progression of geographic atrophy.
Clinical Trials
Lampalizumab has been studied in several clinical trials, including the Phase III MAHALO study. However, the results have been mixed, and the drug has not yet been approved by the Food and Drug Administration (FDA) for the treatment of geographic atrophy.
Related Terms
- Monoclonal Antibody
- Geographic Atrophy
- Age-related Macular Degeneration
- Complement Factor D
- Complement System
- Food and Drug Administration
External links
- Medical encyclopedia article on Lampalizumab
- Wikipedia's article - Lampalizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski